OnAir, with Clinical Respiratory News

How can we reduce the burden of COPD?

Recorded to raise awareness on World COPD Day 2024, this episode of OnAir is dedicated to chronic obstructive pulmonary disease – the third-leading cause of deaths worldwide. But as well as discussing the prevalence, underlying causes and trajectories of the condition, expert guests Professor Jean-Louis Pépin and research scientist Elroy Boers share new perspectives provided by their recent findings on the subject, including: * How real-world evidence can better reflect the complexity and heterogeneity of COPD * Why analysing data on gender and socioeconomic differences can lead to greater understanding of the disease landscape * What real-word evidence tells us about treating COPD patients with NIV Looking to the future, our guests finish on a positive note by discussing the potential beneficial impacts new COPD management strategies could have on patient outcomes and economic and healthcare burdens. Guests: Prof. Jean-Louis Pépin, PU-PH in Clinical Physiology, head of the HP2 research laboratory, Grenoble, France Dr Elroy Boers, Lead Health Research Scientist, ResMed Hosts: Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care. Nina Wiklund is ResMed’s Global Medical Marketing Content Lead, and has a burning enthusiasm for clinical research. She is especially interested in the additional insights and possibilities real-world evidence can add to existing RCTs.  References and useful links: 1. Boers, M. Barrett, J.G. Su, et al. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. JAMA Netw Open. 2023;6(12):e2346598. doi:10.1001/jamanetworkopen.2023.46598 2. Boers, A. Allen, A. Benjafield, L.E. Crotty Alexander, A. Malhotra and M. Barrett. A scenario-based modeling study to project the future burden of COPD in Western Europe accounting for air pollution, tobacco smoking, and e-cigarette vaping. (abstract). ERS 2024. 3. -L Pépin, P. Lemeille, H. Denis, A. Josseran, F. Lavergne, A. Panes, S. Bailly, A. Palot, A. Prigent, Health trajectories before initiation of non-invasive ventilation for chronic obstructive pulmonary disease: a French nationwide database analysis, The Lancet Regional Health - Europe, 2023, 100717, ISSN 2666-7762, doi: 10.1016/j.lanepe.2023.100717. 2 4. J.-L. Pépin, E. Herquelot, H. Denis, A. Josseran, F. Lavergne, A. Schmidt, S. Bailly, A. Palot, A. Prigent, and on behalf of the MedXcloud group. Impact of Long-term Domiciliary Non Invasive Ventilation (NIV) on Severe Exacerbations and Survival in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Nationwide Cohort Study Using Multistate Models (abstract). Am J Respir Crit Care Med 2024;209:A4978. The podcast OnAir, with Clinical Respiratory News (CRN) is a medical education non-promotional for healthcare professionals organised by ResMed. Learn more at https://webinars.resmed.eu/podcasts-list/ [https://webinars.resmed.eu/podcasts-list/]. This podcast is intended for healthcare professionals only. Disclaimer: * This programme is non promotional and is sponsored by ResMed. * The speakers are being compensated and/or receiving an honorarium from ResMed in connection with this programme. * The content contained in this programme was jointly developed by the speakers and ResMed, and is not eligible for continuing medical education (CME) credits. Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in sleep and breathing health. © ResMed

Exploring AI’s role in sleep and breathing health

With 4,300 unique presentations from an estimated 30,000 authors at this year’s ERS, there was a lot of information to absorb… so we invited Dr Meredith Barrett, Vice President of Patient Health Insights at ResMed, who attended the event in Vienna, Austria, to share her highlights. ERS’s theme was ‘Humans and Machines: Getting the Balance Right’ setting the scene for enthusiastic debate about artificial intelligence (AI) and what it means for the future of sleep and breathing health. Meredith distills the main talking points down into two key areas of insight: Potential benefits of AI: * Increasing the accuracy of sleep-disordered breathing diagnostics * Analysing predictive factors for chronic conditions such as COPD and asthma * Detecting patterns in patient data to help personalise care * Improving efficiency and reducing workload for healthcare professionals Questions and concerns about AI: * Whether it could undermine the patient-clinician relationship * The need for research on safety and effectiveness in real-world settings * Ethical questions, such as whether AI could cause biased outcomes * How patient data is handled and accessed As well as exploring these topics with host Daniela Gautschi, Meredith tells us about other aspects of the agenda that caught her attention – with a focus on digital health, novel diagnostics in sleep, understanding the future burden of respiratory disease, and how to promote treatment adherence by understanding a user’s social context. Guest: Dr Meredith Barrett, Vice President, Patient Health Insights, ResMed Host: Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care. References and useful links: 1. Kaye, H.C. Lyson, E. Boers, A. Allen, V.T. Vuong, V. Bala, and M. Barrett. A Mixed-methods Exploration of Patient Perspectives on Pap Therapy Initiation: Implications for Improved Outreach and Education. D102. HOT TOPICS IN BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH. May 1, 2024, A7300-A7300 2. Boers, A. Allen, A. Benjafield, L.E. Crotty Alexander, A. Malhotra and M. Barrett. A scenario-based modeling study to project the future burden of COPD in Western Europe accounting for air pollution, tobacco smoking, and e-cigarette vaping. (abstract). ERS 2024. 3. Kaye, L., Vuong, V., Benjafield, A., Gupta, P., & Barrett, M. (2024). Role of Partnership in Positive Airway Pressure (PAP) Therapy Adoption in Obstructive Sleep Apnea. Eur Respiratory Soc 2024 (abstract) 4. Kaye, L., Vuong, V., Benjafield, A., Gupta, P., & Barrett, M. (2024). The association between behavioral clusters and short-term PAP usage in OSA. Eur Respiratory Soc 2024 (abstract) 5. Zack, Travis et al. (2024) Assessing the potential of GPT-4 to perpetuate racial and gender biases in health care: a model evaluation study. The Lancet Digital Health, Volume 6, Issue 1, e12 – e22. doi: 10.1016/S2589-7500(23)00225-X The podcast OnAir, with Clinical Respiratory News (CRN) is a medical education non-promotional for healthcare professionals organised by ResMed. Learn more at https://webinars.resmed.eu/podcasts-list/ [https://webinars.resmed.eu/podcasts-list/]. This podcast is intended for healthcare professionals only. Disclaimer: * This programme is non promotional and is sponsored by ResMed. * The speakers are being compensated and/or receiving an honorarium from ResMed in connection with this programme. * The content contained in this programme was jointly developed by the speakers and ResMed, and is not eligible for continuing medical education (CME) credits. Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in sleep and breathing health. © ResMed

Women and OSA: Breaking barriers to diagnosis and treatment

While research has shown that women who are diagnosed and treated for OSA may experience greater improvements in quality of life scores and higher CPAP usage than men1, actually getting a diagnosis in the first place can be an uphill struggle. So in this episode of OnAir we invite two leading experts on the topic, Prof. Sophia Schiza and Dr Alison Wimms, to explain why this is – and what can be done so more women with OSA can enjoy the benefits of therapy sooner and for longer... They have a lot to say on the subject, so we’ve divided up the recording by questions, so you can focus on the areas that interest you the most, or listen to it as a whole – the choice is yours!: Introduction * 00:51 Schiza: Why is this an important topic? * 03:09 Dr Wimms: What has kept you interested in this topic? Differences between OSA presentation in men and women * 05:02 What are the main symptoms of OSA for male and female patients? * 09:06 How can we see differences in patients’ diagnostic traces? * 11:51 Why do these differences exist? * 11:06 Are there also difference between the sexes when it comes to treatment acceptance and response? * 21:25 Are there any other differences to highlight? Deep dive into female OSA research * 27:25 Tell us more about the UK MERGE-data for mild OSA1... * 33:54 ...and the ESADA-publication2 about OSA phenotypes where gender is one of the parameters of weight in the spider charts displaying patient characteristics? Conclusion * 43:31 What is the most important practical advice for clinicians who see women every day and want to help those with sleep apnoea? Guests: Prof. Sophia Schiza, Head of the ERS Assembly 4 Sleep Disordered Breathing and head of Sleep Disorders Center, Department of Respiratory Medicine at the School of Medicine, University of Crete, Greece Dr Alison Wimms, Director of Medical Affairs in Clinical Research, ResMed Hosts: Nina Wiklund is ResMed’s Global Medical Marketing Content Lead, and has a burning enthusiasm for clinical research. She is especially interested in the additional insights and possibilities real-world evidence can add to existing RCTs.  Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care. References and useful links: 1. Wimms AJ, Kelly JL, Turnbull CD, McMillan A, Craig SE, O'Reilly JF, Nickol AH, Decker MD, Willes LA, Calverley PMA, Benjafield AV, Stradling JR, Morrell MJ; MERGE Trial Investigators. Mild obstructive sleep apnoea in females: post hoc analysis of the MERGE randomised controlled trial. ERJ Open Res. 2024 Feb 5;10(1):00574-2023. doi: https://doi.org/10.1183/23120541.00574-2023 [https://doi.org/10.1183/23120541.00574-2023] PMID: 38333643; PMCID: PMC10851951. 2. Yassen A, Coboeken K, Bailly S, Burghaus R, Buskova J, Dogas Z, Drummond M, Gouveris H, Joppa P, Lippert J, Lombardi C, Mihaicuta S, Pépin JL, Zou D, Hedner J, Grote L. Baseline clusters and the response to positive airway pressure treatment in obstructive sleep apnoea patients: longitudinal data from the European Sleep Apnea Database cohort. ERJ Open Res. 2022 Oct 31;8(4):00132-2022. doi: https://doi.org/10.1183/23120541.00132-2022 [https://doi.org/10.1183/23120541.00132-2022] PMID: 36329798; PMCID: PMC9619251. The podcast OnAir, with Clinical Respiratory News (CRN) is a medical education non-promotional for healthcare professionals organised by ResMed. Learn more at https://webinars.resmed.eu/podcasts-list/ [https://webinars.resmed.eu/podcasts-list/]. This podcast is intended for healthcare professionals only. Disclaimer: * This programme is non promotional and is sponsored by ResMed. * The speakers are being compensated and/or receiving an honorarium from ResMed in connection with this programme. * The content contained in this programme was jointly developed by the speakers and ResMed, and is not eligible for continuing medical education (CME) credits. Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in sleep and breathing health. © ResMed

Home high-flow therapy: the Danish approach

In this episode of OnAir Professor Ulla Møller Weinreich, Head of the Danish Lung Society, explains the why, who and how of the national guidelines for home HFT her team created in 20191, including: * Why they started using home HFT and the clinical benefits they discovered, including reduced dyspnoea, easier work of breathing and improved mucus clearance, 2 and cost-effectiveness of the treatment.3 * Which patients benefit the most from the treatment – and how it can ease some of the physiological strains experienced by those with COPD or bronchiectasis. * How clinicians can initiate HFT with patients, starting by defining clear indications and treatment goals, before moving on to practical considerations such as setting the right flow and choosing the right cannula. Guest: Professor Ulla Møller Weinreich - Head of the Respiratory Research Unit, Aalborg University Hospital, Denmark, and Head of the Danish Lung Society Host: Nina Wiklund is ResMed’s Global Medical Marketing Content Lead, and has a burning enthusiasm for clinical research. She is especially interested in the additional insights and possibilities real-world evidence can add to existing RCTs.  References and useful links: 1. Storgaard LH, Hockey H, Laursen BS, Weinreich UM. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis. 2018;13:1195-1205. https://doi.org/10.2147/COPD.S159666 [https://doi.org/10.2147/COPD.S159666] 2. Weinreich, U. M., Juhl, K. S., Søby Christophersen, M., Gundestrup, S., Hanifa, M. A., Jensen, K., … Storgaard, L. H. (2023). The Danish respiratory society guideline for long-term high flow nasal cannula treatment, with or without supplementary oxygen. European Clinical Respiratory Journal, 10(1). https://doi.org/10.1080/20018525.2023.2178600 [https://doi.org/10.1080/20018525.2023.2178600] 3. Sørensen SS, Storgaard LH, Weinreich UM. Cost-Effectiveness of Domiciliary High Flow Nasal Cannula Treatment in COPD Patients with Chronic Respiratory Failure. Clinicoecon Outcomes Res. 2021;13:553-564 https://doi.org/10.2147/CEOR.S312523 [https://doi.org/10.2147/CEOR.S312523] The podcast OnAir, with Clinical Respiratory News (CRN) is a medical education non-promotional for healthcare professionals organised by ResMed. Learn more at https://webinars.resmed.eu/podcasts-list/ [https://webinars.resmed.eu/podcasts-list/]. This podcast is intended for healthcare professionals only. Disclaimer: * This programme is non promotional and is sponsored by ResMed. * The speakers are being compensated and/or receiving an honorarium from ResMed in connection with this programme. * The content contained in this programme was jointly developed by the speakers and ResMed, and is not eligible for continuing medical education (CME) credits. Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in sleep and breathing health. © ResMed

ASV: using real-world evidence for real-life insights

In this episode of OnAir, host Daniela Gautschi is joined by two experts in ASV therapy* and real-world evidence: Prof. Michael Arzt (READ-ASV registry1, 2) and Prof. Renaud Tamisier (FACE-cohort3, 4 and FACIL-VAA5 registries). Experience shows that ASV can improve symptoms and quality of life for some patients with central sleep apnoea. But which patients are most likely to benefit and why? By performing large-scale database analyses, Prof. Arzt and Prof. Tamisier have been able to identify clinically meaningful clusters of CSA patients, explore phenotypes that have yet to be studied by RCTs, and shed light on the critical role played by sleep, respiratory and cardiovascular comorbidities. Listen now to understand how this research could transform the diagnosis, treatment and prognosis of patients with persistent CSA and Treatment-Emergent CSA. Guests: Prof. Michael Arzt - Professor of Internal Medicine, University Hospital Regensburg, Germany Prof. Renaud Tamisier - Professor of Clinical Physiology, Grenoble Alpes University and Director of the Sleep Exploration Centre, Grenoble Alpes University Hospital, France Host: Daniela Gautschi is ResMed’s Director Clinical Advocacy Europe, and has a passion for exploring the latest developments in the world of sleep and breathing health. Her key focus is advocating for digital health innovations to help ensure access to good quality care. References and useful links: 1. Arzt M, Munt O, Pépin J-L, et al. Registry on the Treatment of Central and Complex Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV): protocol and cohort profile. ERJ Open Res 2023; 9: 00618-2022 [DOI: https://doi.org/10.1183/23120541.00618-2022 [https://doi.org/10.1183/23120541.00618-2022]] 2. Arzt M, Munt O, Pépin JL, Heinzer R, Kübeck R, von Hehn U, Ehrsam-Tosi D, Benjafield AV, Woehrle H. Effects of Adaptive Servo-Ventilation on Quality of Life: The READ-ASV Registry. Ann Am Thorac Soc. 2024 Jan 19. doi: https://doi.org/10.1513/AnnalsATS.202310-908OC [https://doi.org/10.1513/AnnalsATS.202310-908OC] 3. Tamisier R, Damy T, Bailly S FACE study investigators, et al; Adaptive servo ventilation for sleep apnoea in heart failure: the FACE study 3-month data. Thorax 2022;77:178-185. https://thorax.bmj.com/content/77/2/178 [https://thorax.bmj.com/content/77/2/178] 4. Tamisier R, Damy T, Bailly S, Goutorbe F, Davy JM, Lavergne F, Palot A, Verbraecken JA, d'Ortho MP, Pépin JL; FACE investigators; Steering committee members; d'Ortho MP, Pépin JL, Davy JM, Damy T, Tamisier R; FACE study investigators. FACE study: 2-year follow-up of adaptive servo-ventilation for sleep-disordered breathing in a chronic heart failure cohort. Sleep Med. 2024 Jan;113:412-421. doi: https://doi.org/10.1016/j.sleep.2023.07.014 [https://doi.org/10.1016/j.sleep.2023.07.014] 5. Observational Multicenter Cohort Study of French Patients With a Central or Combined Syndrome of Sleep Apnea With a Predominant Central SAS Treated by Adaptive Servo-Ventilation (FACIL-VAA) https://clinicaltrials.gov/study/NCT02835638 [https://clinicaltrials.gov/study/NCT02835638] * ERS workshop replay: The indication of use of ASV therapy, from evidence to clinical practice [https://webinars.resmed.eu/webinar/the-indication-of-use-of-asv-therapy-from-evidence-to-clinical-practice/] *ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea. The podcast OnAir, with Clinical Respiratory News (CRN) is a medical education non-promotional for healthcare professionals organised by ResMed. Learn more at https://webinars.resmed.eu/podcasts-list/ [https://webinars.resmed.eu/podcasts-list/]. This podcast is intended for healthcare professionals only. Disclaimer: * This programme is non promotional and is sponsored by ResMed. * The speakers are being compensated and/or receiving an honorarium from ResMed in connection with this programme. * The content contained in this programme was jointly developed by the speakers and ResMed, and is not eligible for continuing medical education (CME) credits. Listen to OnAir with Clinical Respiratory News, the podcast that brings you fresh insights and thought-provoking discussions about hot topics in sleep and breathing health. © ResMed